For the quarter ending 2025-09-30, KYTX had -$19,276K decrease in cash & cash equivalents over the period. -$43,323K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -36,787 | -86,716 |
| Stock-based compensation | 2,699 | 4,679 |
| Accretion of discounts on available-for-sale marketable securities | 1,567 | 3,953 |
| Depreciation and amortization expense | 415 | 1,016 |
| Impairment of capitalized software | 0 | 648 |
| Loss on disposal of property and equipment | -40 | - |
| Non-cash lease expense | 732 | 1,419 |
| Prepaid expense and other current assets | 1,137 | -1,972 |
| Other non-current assets | 958 | 505 |
| Accounts payable | -6,801 | 5,193 |
| Accrued compensation | 1,989 | 88 |
| Other accrued expenses and current liabilities | -1,172 | 1,016 |
| Other non-current liabilities | 0 | - |
| Operating lease liability | -774 | -1,721 |
| Net cash used in operating activities | -43,321 | -76,864 |
| Purchases of available-for-sale marketable securities | 72,821 | 175,851 |
| Proceeds from maturities of available-for-sale marketable securities | 95,700 | 210,800 |
| Internal-use software development costs capitalized in other non-current assets | 390 | 200 |
| Proceeds from sale of property and equipment | 70 | - |
| Purchases of property and equipment | 2 | 4 |
| Net cash provided by (used in) investing activities | 22,557 | 34,745 |
| Proceeds from issuance of common stock upon initial public offering, net of underwriting commissions | 0 | 0 |
| Proceeds from exercise of common stock options | 1,651 | 3 |
| Principal paid on finance lease liabilities | 120 | 603 |
| Payments for offering costs | 0 | 412 |
| Taxes paid related to net share settlement upon vesting of restricted stock units | 43 | 51 |
| Net cash provided by financing activities | 1,488 | -1,063 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | -19,276 | -43,182 |
| Cash and cash equivalents at beginning of period | 97,173 | - |
| Cash and cash equivalents at end of period | 34,715 | - |
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)